BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

June 23, 2014 7:00 AM UTC

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) gained $3.69 to $72.24 on Friday after FDA approved an NDA for Cubist's Sivextro tedizolid to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by certain susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Sivextro is also under EMA review to treat complicated skin and soft tissue infections (cSSTIs).

Earlier in the week, FDA accepted and granted Priority Review to an NDA for ceftolozane/tazobactam to treat complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs). The PDUFA date is Dec. 21. The company plans to submit an MAA to EMA next half...